On November 19th, MTS Health Partners' Evan Matlin will be speaking on a panel for BioCentury Inc. & BioIndustry Association (BIA) 2nd CEO & Investor Dialogue entitled “Pharma & Investor Roundtable: Delivering on the Biotech Story”. This exciting panel will discuss navigating the toughest downturn in biotech history, the challenges for CEOs and Boards, and how to deliver results in uncertain markets. ✅ Register https://lnkd.in/g7gNCTNd #biotech #biopharma #healthcare #mtshealthpartners
MTS Health Partners’ Post
More Relevant Posts
-
Due to record demand, we are now sold out of in-person passes to attend Bio€quity Europe in San Sebastián. You may still attend this VIP event via a Digital Pass, which allows you to: ➤ Schedule virtual partnering meetings with Bio€quity delegates May 21-22 ➤ Watch all session recordings for 30 days after the event. ➤ Receive the exclusive conference report from Insights Partner McKinsey & Company plus the Bio€quity “Scene Setter” report from BioCentury Inc. Register for a digital pass: https://loom.ly/HNklMqQ If you wish to attend #BioEquityEurope in-person, please join the Wait List: https://loom.ly/mo-dKj0 Those on the Wait List who have registered for a Digital Pass will receive priority review. Please ensure you have an in-person ticket before you book travel. #biotech #biopharma #venturecapital #drugdevelopment #businessdevelopment #pharma #investor #investors #lifesciences #VCs
-
-
Take a moment to read our latest thinking from EMEA Thought Leadership. In this piece we explore how clinical trial outcomes impact biotech valuations and examine the underlying drivers, such as how trial results compare to investors' prior expectations, development phase at readout, therapy area or trial design. #Biotech #IQVIABIOTECH. Get in touch to learn more.
#Biotech valuations respond to clinical trial results, as moments of truth, as investors re-calibrate their expectations. IQVIA Thought Leaders Markus Gores and William Harries delve into the drivers of value inflection and strategic decision-making. Read now: https://bit.ly/4c7oJeq #biopharma
-
-
#Biotech is a tricky industry for investors. #ClinicalTrials are share price catalysts and can wildly affect a biotech's #valuation. However, not all events react equally and this depends on therapy area and trial stage. Our team analysed a universe of events to unravel the factors affecting valuation swings and we provide recommendations on how to make strategic decisions to crystallise the value of R&D assets.
#Biotech valuations respond to clinical trial results, as moments of truth, as investors re-calibrate their expectations. IQVIA Thought Leaders Markus Gores and William Harries delve into the drivers of value inflection and strategic decision-making. Read now: https://bit.ly/4c7oJeq #biopharma
-
-
Thrilled to be participating in today’s #BioEquity Europe discussion: “Dealmakers Showcase: How to Grab the Attention of Pharma BD&L Execs.” Join me and the other panelists at 2pm as we delve into what biotechs must do to rise above the noise to secure partnerships that drive innovation and growth with big pharma. I look forward to connecting with fellow leaders and innovators who are shaping the future of healthcare. #BioEquity #JNJInnovation
-
-
Ever wondered how a clinical trial result, positive or negative, might affect the valuation of an emerging #biopharma company? How might this be modulated by the stage of the trial, or the therapy area the product is being trialed for? Our #IQVIA EMEA Thought Leadership paper answers these questions with a rigorous, statistically robust analysis. Download now!
#Biotech valuations respond to clinical trial results, as moments of truth, as investors re-calibrate their expectations. IQVIA Thought Leaders Markus Gores and William Harries delve into the drivers of value inflection and strategic decision-making. Read now: https://bit.ly/4c7oJeq #biopharma
-
-
Our latest white paper from #IQVIA Thought Leadership explores the impact of #trialreadouts on #biotech #valuations. A must read for biotech management teams and investors alike.
#Biotech valuations respond to clinical trial results, as moments of truth, as investors re-calibrate their expectations. IQVIA Thought Leaders Markus Gores and William Harries delve into the drivers of value inflection and strategic decision-making. Read now: https://bit.ly/4c7oJeq #biopharma
-
-
If you haven't read this whitepaper, I strongly recommend downloading it to gain a comprehensive understanding of how trial results impact Biotech investors. It might just surprise you. #IQVIA #valuecreation #clinicaltrialresults
#Biotech valuations respond to clinical trial results, as moments of truth, as investors re-calibrate their expectations. IQVIA Thought Leaders Markus Gores and William Harries delve into the drivers of value inflection and strategic decision-making. Read now: https://bit.ly/4c7oJeq #biopharma
-
-
📢 We are less than two weeks away from the opening of the second cycle of this year’s funding round! New information is now available on the CARB-X website, including additional Target Product Profiles for the therapeutics and preventative themes as well as clarifications to minimal entry criteria. Do you have questions about the scope of the funding round or the application process? Take a look at our Frequently Asked Questions. 🔗 View here: bit.ly/3W3TKcs 📥 Sign up for the CARB-X newsletter to be notified when the Portal opens: carb-x.org/sign-up/ #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #antibiotics
-
-
Part 1 of our BRAVE Launch Challenges report is now complete – thank you to the 50+ industry leaders who responded to our survey last month. Part 2 of the process will be taking place over the coming weeks as we delve into the survey results at our in-person and online roundtable meetings. We will explore the key themes and how some of these challenges could be tackled. If you would like to be part of the conversation and participate in these roundtable meetings, please email us at hello@onlythebrave.uk or react to this post if you would be interested in attending! #BRAVElaunch #BRAVEteam #medcomms #pharma #biotech #medical #productlaunchstrategy #health
-
Headlines from our launch survey. Access is the biggest barrier to launch success. Want to know more? Want to discuss the findings with your peers? Call BRAVE 📞
Part 1 of our BRAVE Launch Challenges report is now complete – thank you to the 50+ industry leaders who responded to our survey last month. Part 2 of the process will be taking place over the coming weeks as we delve into the survey results at our in-person and online roundtable meetings. We will explore the key themes and how some of these challenges could be tackled. If you would like to be part of the conversation and participate in these roundtable meetings, please email us at hello@onlythebrave.uk or react to this post if you would be interested in attending! #BRAVElaunch #BRAVEteam #medcomms #pharma #biotech #medical #productlaunchstrategy #health
